Drug Profile
Aflibercept sustained release - Regeneron/Ocular Therapeutix
Alternative Names: Aflibercept punctal plug - Regeneron/Ocular Therapeutix; Aflibercept suprachoroidal injection - Regeneron/Ocular Therapeutix; anti-VEGF antibody implant; OTX IVT; OTX-AFSLatest Information Update: 21 Nov 2021
Price :
$50
*
At a glance
- Originator Ocular Therapeutix; Regeneron Pharmaceuticals
- Class Antineoplastics; Eye disorder therapies; Immunoglobulin Fc fragments; Immunoglobulin fragments; Recombinant fusion proteins
- Mechanism of Action Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diabetic macular oedema; Retinal vein occlusion; Wet age-related macular degeneration
Most Recent Events
- 05 Aug 2021 regeneron Pharmaceuticals terminates its option and license agreement collaboration with Ocular Therapeutix for Aflibercept sustained release
- 05 Aug 2021 Discontinued - Preclinical for Diabetic macular oedema in USA (Intravitreous)
- 05 Aug 2021 Discontinued - Preclinical for Retinal vein occlusion in USA (Intravitreous)